MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
JPM | Free Full-Text | MET Gene Dysregulation as a Promising Therapeutic Target in Lung Cancer—A Review
Safety and Tolerability of c-MET Inhibitors in Cancer. - Abstract - Europe PMC
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
Frontiers | Resistance to KRASG12C Inhibitors in Non-Small Cell Lung Cancer
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
New Drug Product: Tabrecta - MPR
Complications following novel therapies for non‐small cell lung cancer - Skribek - 2022 - Journal of Internal Medicine - Wiley Online Library
Frontiers | Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
A New Type of Recyclable: Finding New Uses for Established Drugs｜Tokyo Medical and Dental University, National University Corporation
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Amivantamab mechanisms of action | Download Scientific Diagram
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
